VolitionRx Expands Fujifilm Vet Systems Agreement to Develop Feline Cancer Test in Japan

VolitionRx's expanded agreement with Fujifilm Vet Systems to develop a feline cancer test in Japan opens a potential revenue stream in a market with nearly 9 million cats and advances early cancer detection for pets.

Chicago Metrowire Staff
••Healthcare
VolitionRx Expands Fujifilm Vet Systems Agreement to Develop Feline Cancer Test in Japan

VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, has expanded its supply agreement with Fujifilm Vet Systems Co. Ltd. in Japan to include the development and use of its Nu.Q Vet Feline Test. The agreement builds on the July 2024 launch of the Nu.Q Vet Canine Test in Japan, where growing veterinary demand prompted the introduction of an automated version earlier this year. The expansion follows research demonstrating high accuracy for a prototype feline assay in detecting lymphoma, the most common cancer in cats. Fujifilm plans to conduct an additional study with veterinary oncologists in Japan.

The implications of this announcement are significant for both animal health and Volition's commercial prospects. Japan's feline population approaches 9 million, representing a substantial potential revenue opportunity for the company. By extending its existing canine testing technology to cats, Volition aims to make cancer screening a routine component of annual veterinary wellness examinations. This shift could lead to earlier cancer detection in cats, improving outcomes and potentially prolonging lives. The collaboration with Fujifilm Vet Systems, a well-established player in the Japanese veterinary market, provides Volition with a strategic partner to navigate regulatory and market dynamics while leveraging Fujifilm's distribution network.

Volition is continuing product development of the blood-based feline cancer test, with plans to launch it on the Immunodiagnostic Systems (IDS) i10 automated analyzer platform. This platform choice suggests a focus on scalability and efficiency, as automated testing can handle higher volumes and reduce turnaround times. The move aligns with Volition's broader mission to advance epigenetics for earlier disease detection in both humans and animals. As Volition continues to develop simple, easy-to-use, cost-effective blood tests, the expansion into feline cancer testing could set a precedent for routine screening in veterinary medicine, similar to human preventive care.

The announcement also highlights the growing interest in pet healthcare innovation. With advancements in veterinary diagnostics, pet owners are increasingly willing to invest in advanced care for their animals. Volition's partnership with Fujifilm Vet Systems positions both companies to capitalize on this trend. The additional study with veterinary oncologists in Japan will be crucial for validating the test's clinical utility and building trust among practitioners. If successful, the feline test could become a standard tool in Japanese veterinary clinics, driving adoption and revenue.

For investors, the expanded agreement signals Volition's commitment to commercializing its Nu.Q Vet platform and diversifying its revenue streams beyond human diagnostics. The company's ability to secure and expand partnerships with major industry players like Fujifilm Vet Systems demonstrates confidence in its technology. As the feline test progresses toward launch, Volition may seek to replicate this model in other markets, potentially unlocking further growth opportunities. The full press release can be viewed at https://ibn.fm/6fgSw.

InvestorWire (InvestorWire), a specialized communications platform, distributed the announcement as part of its corporate communications solutions, which include editorial syndication to 5,000+ outlets and social media distribution. For full terms of use and disclaimers, visit https://www.InvestorWire.com/Disclaimer.

Blockchain Registration

QR Code for Blockchain Registration